This video is created and funded by Biogen. It is created for healthcare professionals for the sole purpose of medical education. At this time, there are no therapies approved that are directed at tau. There are investigational drugs in clinical trials and the safety profile and efficacy of those drugs have yet to be established.
The speakers have been compensated by Biogen for their involvement.
In this video, Lawren VandeVrede and Douglas Scharre discuss the biologic and clinical significance of tau in Alzheimer’s disease (AD) including:
- Current understanding of tau’s role in the underlying biology of AD
- How tau pathology relates to clinical presentation and disease severity
- Distinctions between tau loss-of-function and gain-of-function mechanisms
- The evolving role of blood-based biomarkers
If you enjoyed this content and would like to learn more about tau and its role in AD, please visit KnowTau at www.knowtau.com. Know Tau has been created and funded by Biogen and is intended for healthcare professionals.
Speakers:
Lawren VandeVrede1
Douglas Scharre2
Moderator:
Ivana Rubino3
1. University of California San Francisco, USA
2. Ohio State University Wexner Medical Center, Columbus, USA
3. Biogen, Cambridge, Massachusetts, USA
References:
1. Collij LE et al. Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease. Nat Commun. 2024;15(1):8061.
2. Oh HS et al. A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease. Nat Med. 2025;31(5):1592-603.
3. FDA. FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease. Available at: https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease. Last accessed: 18 August 2025.
Biogen-280672
Date of preparation: March 2026
